Nicholas Smith is currently a financial analyst for Yahoo. He graduated from Creighton University with majors in finance and accounting. He has over three years of experience working as an analyst in a variety of fields, including investment research, corporate FP&A and private equity. His three years working as an analyst combined with the experience he has obtained trading stocks over the past five years have provided him with a unique perspective on the financial markets.
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).
Have been an investor for 60 years. Last 20 years have concentrated on biotechs. Have been senior exec with Shell and ITT before retiring 30+ years ago. My working areas were finance, informatics and international management. Taught MBA courses in management, informatics and communications. Speak French and Spanish plus some German.
i am a custom harvester,have worked in the ohio oil fields,and love to make money on the market.My most traded stocks are related to oil and gas.some companys i worked for were new frontier ex,belden&blake,sherman drilling,armstrong drilling.mostly as a cat skiner,but spent time on rigs also.
John Hodge is an active trader who follows the technology/biotech sector specifically. I have been successfully trading stocks for the last 16 years and still thank those that pointed me in the direction of Qualcomm and Amgen many years ago. I believe research and timing is the key to long term goal attainment in the market.